External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma

Nathan E. Hoffmann, Yuri Sheinin, Christine M. Lohse, Alexander S. Parker, Bradley C. Leibovich, Zhong Jiang, Eugene D. Kwon

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

BACKGROUND. High-quality external validation studies have recently been high-lighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS. The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS. It was observed that 213 ccRCC specimens (29.8%) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42% increase in the risk of death from RCC (hazards ratio [HR], 1.42; P = .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P < .001). CONCLUSIONS. Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.

Original languageEnglish (US)
Pages (from-to)1471-1479
Number of pages9
JournalCancer
Volume112
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Renal Cell Carcinoma
Neoplasms
Neoplasm Metastasis
Insulin-Like Growth Factor II
Validation Studies
Carrier Proteins
Necrosis
Biomarkers
Messenger RNA

Keywords

  • Biomarker
  • Cancer progression
  • IMP3
  • Insulin-like growth factor
  • Kidney cancer
  • mRNA binding protein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. / Hoffmann, Nathan E.; Sheinin, Yuri; Lohse, Christine M.; Parker, Alexander S.; Leibovich, Bradley C.; Jiang, Zhong; Kwon, Eugene D.

In: Cancer, Vol. 112, No. 7, 01.04.2008, p. 1471-1479.

Research output: Contribution to journalArticle

Hoffmann, Nathan E. ; Sheinin, Yuri ; Lohse, Christine M. ; Parker, Alexander S. ; Leibovich, Bradley C. ; Jiang, Zhong ; Kwon, Eugene D. / External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. In: Cancer. 2008 ; Vol. 112, No. 7. pp. 1471-1479.
@article{f67123fd4d3f45f9b07f8c40d0fae45c,
title = "External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma",
abstract = "BACKGROUND. High-quality external validation studies have recently been high-lighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS. The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS. It was observed that 213 ccRCC specimens (29.8{\%}) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42{\%} increase in the risk of death from RCC (hazards ratio [HR], 1.42; P = .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P < .001). CONCLUSIONS. Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.",
keywords = "Biomarker, Cancer progression, IMP3, Insulin-like growth factor, Kidney cancer, mRNA binding protein",
author = "Hoffmann, {Nathan E.} and Yuri Sheinin and Lohse, {Christine M.} and Parker, {Alexander S.} and Leibovich, {Bradley C.} and Zhong Jiang and Kwon, {Eugene D.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1002/cncr.23296",
language = "English (US)",
volume = "112",
pages = "1471--1479",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma

AU - Hoffmann, Nathan E.

AU - Sheinin, Yuri

AU - Lohse, Christine M.

AU - Parker, Alexander S.

AU - Leibovich, Bradley C.

AU - Jiang, Zhong

AU - Kwon, Eugene D.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - BACKGROUND. High-quality external validation studies have recently been high-lighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS. The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS. It was observed that 213 ccRCC specimens (29.8%) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42% increase in the risk of death from RCC (hazards ratio [HR], 1.42; P = .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P < .001). CONCLUSIONS. Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.

AB - BACKGROUND. High-quality external validation studies have recently been high-lighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS. The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS. It was observed that 213 ccRCC specimens (29.8%) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42% increase in the risk of death from RCC (hazards ratio [HR], 1.42; P = .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P < .001). CONCLUSIONS. Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.

KW - Biomarker

KW - Cancer progression

KW - IMP3

KW - Insulin-like growth factor

KW - Kidney cancer

KW - mRNA binding protein

UR - http://www.scopus.com/inward/record.url?scp=41149145266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149145266&partnerID=8YFLogxK

U2 - 10.1002/cncr.23296

DO - 10.1002/cncr.23296

M3 - Article

VL - 112

SP - 1471

EP - 1479

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -